Clinical trial Archives

News and Trends 25 Jul 2023

Crescendo Biologics raises $32M and expands cancer trial

Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has announced that it plans to augment the ongoing phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major […]

July 25, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

Biomica announces interim positive results from irritable bowel syndrome program

Biomica Ltd., a clinical-stage biopharmaceutical company developing microbiome-based therapeutics, has released interim positive results from pre-clinical studies in its irritable bowel syndrome (IBS) program. The work was performed in collaboration with the lab of Kara Gross Margolis, associate director for clinical and translational research for the New York University Pain Research Center and an associate […]

July 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 19 Jul 2023

Moleculin issues acute myeloid leukemia drug data

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with drug candidates targeting hard-to-treat tumors and viruses, has published data from its completed MB-105 European phase 1 clinical trial assessing the safety and efficacy of annamycin as a single agent for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). ‘Results of a […]

July 19, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jul 2023

Hope for Alzheimer’s patients after Lilly drug results

Eli Lilly and Company has presented full results from its phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD). The data were shared at the 2023 Alzheimer’s Association International Conference (AAIC) as a featured symposium and simultaneously published in the Journal of […]

July 17, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 14 Jul 2023

TME Pharma provides positive glioblastoma trial results

TME Pharma N.V. has announced a positive clinical update on the best response to therapy, reporting one patient achieving complete response in the GLORIA expansion arm evaluating NOX-A12, TME Pharma’s CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab, in first-line glioblastoma. TME Pharma is a biotechnology company focused on developing novel […]

July 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 14 Jul 2023

Calliditas reveals ‘encouraging results’ from head and neck cancer trial

Calliditas Therapeutics AB has announced interim data from its proof-of-concept phase 2 trial in patients with squamous cell carcinoma of the head and neck (SCCHN) with its lead NOX 1 and 4 inhibitor product candidate, setanaxib. The analysis reflects encouraging early clinical progression-free survival (PFS) results and is supportive of the presumed anti fibrotic mode […]

July 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

ADC Therapeutics pauses clinical trial following patient deaths

ADC Therapeutics SA has announced a voluntary pause in the enrollment of new patients in the phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The action was taken by ADC Therapeutics after a recent review of aggregate data […]

July 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Jul 2023

NodThera first to show reduction in neuroinflammation with inflammasome inhibitor

NodThera has announced positive, initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects of its lead candidate NT-0796 on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF). NodThera is a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Alan […]

July 11, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology

CytoMed Therapeutics Limited, a Singapore-based biopharma company focused on novel donor cell-based immunotherapies for the treatment of various cancers, has announced that its CAR-gamma delta T cell (CAR-γδ T cell) technology, which it has licensed from A*STAR, has been granted a patent by the US Patent and Trademark Office (USPTO). The patent covers technologies for […]

July 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

TolerogenixX expands trial and closes €12M financing

TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant patients has received the green light to initiate the B arm of the study. This arm consists of patients receiving minimal immune suppression […]

July 7, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

Positive data from Sensorion hearing loss study

Sensorion, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has reported further analysis from its Proof of Concept (POC) phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation. In June 19, Sensorion announced that in preliminary […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

AstraZeneca non-small cell lung cancer drug meets primary endpoint

Positive high-level results from AstraZeneca’s TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy. […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

Crescendo Biologics raises $32M and expands cancer trial

Biomica announces interim positive results from irritable bowel syndrome program

Moleculin issues acute myeloid leukemia drug data

Hope for Alzheimer’s patients after Lilly drug results

TME Pharma provides positive glioblastoma trial results

Calliditas reveals ‘encouraging results’ from head and neck cancer trial

ADC Therapeutics pauses clinical trial following patient deaths

NodThera first to show reduction in neuroinflammation with inflammasome inhibitor

CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology

TolerogenixX expands trial and closes €12M financing

Positive data from Sensorion hearing loss study

AstraZeneca non-small cell lung cancer drug meets primary endpoint

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!